QR12000
/ Createrna
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 31, 2026
A multicenter, randomized, double-blind, positive drug parallel-controlled clinical study to evaluate the efficacy and safety of QR12000 Compound Tablets and Sacubitril-Valsartan Sodium Tablets for the treatment of patients with moderate and severe essential hypertension
(ChiCTR)
- P3 | N=810 | Recruiting | Sponsor: Peking University First Hospital; Peking University First Hospital
New P3 trial • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1